🟢 Revolution Medicines is trading 4.7% up today after Goldman Sachs initiated coverage at Buy

Revolution Medicines is trading at $199.74, up 4.72%, after Goldman Sachs initiated coverage with a Buy rating and a $267 price target on September 24, 2026.

• The move comes despite broad declines in biotechnology stocks, with company-specific analyst optimism outweighing sector pressure.
• FDA Breakthrough Therapy Designation for RASONQUE remains supportive background; it was announced September 14.